A rare case of septic shock due to Neisseria meningitidis serogroup B infection despite prior vaccination in a young adult with paroxysmal nocturnal haemoglobinuria receiving eculizumab

Dominik Reher; Valentin Fuhrmann; Stefan Kluge; Axel Nierhaus

doi:10.1016/j.vaccine.2018.03.087

A rare case of septic shock due to Neisseria meningitidis serogroup B infection despite prior vaccination in a young adult with paroxysmal nocturnal haemoglobinuria receiving eculizumab

Standard

A rare case of septic shock due to Neisseria meningitidis serogroup B infection despite prior vaccination in a young adult with paroxysmal nocturnal haemoglobinuria receiving eculizumab. / Reher, Dominik; Fuhrmann, Valentin ; Kluge, Stefan ; Nierhaus, Axel.

in: VACCINE, Jahrgang 36, Nr. 19, 03.05.2018, S. 2507-2509.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Reher, D, Fuhrmann, V , Kluge, S & Nierhaus, A 2018, 'A rare case of septic shock due to Neisseria meningitidis serogroup B infection despite prior vaccination in a young adult with paroxysmal nocturnal haemoglobinuria receiving eculizumab', VACCINE, Jg. 36, Nr. 19, S. 2507-2509. https://doi.org/10.1016/j.vaccine.2018.03.087

APA

Reher, D., Fuhrmann, V., Kluge, S., & Nierhaus, A. (2018). A rare case of septic shock due to Neisseria meningitidis serogroup B infection despite prior vaccination in a young adult with paroxysmal nocturnal haemoglobinuria receiving eculizumab. VACCINE, 36(19), 2507-2509. https://doi.org/10.1016/j.vaccine.2018.03.087

Vancouver

Reher D, Fuhrmann V , Kluge S , Nierhaus A. A rare case of septic shock due to Neisseria meningitidis serogroup B infection despite prior vaccination in a young adult with paroxysmal nocturnal haemoglobinuria receiving eculizumab. VACCINE. 2018 Mai 3;36(19):2507-2509. https://doi.org/10.1016/j.vaccine.2018.03.087

Bibtex

@article{81ab1dd4da8644529562e55f33605c26,

title = "A rare case of septic shock due to Neisseria meningitidis serogroup B infection despite prior vaccination in a young adult with paroxysmal nocturnal haemoglobinuria receiving eculizumab",

abstract = "Paroxysmal nocturnal haemoglobinuria (PNH) is a rare acquired haematopoietic stem cell disease which causes defects in complement inhibiting proteins. The disease presents classically with the triad of haemolytic anaemia, pancytopenia and thrombosis. Eculizumab, a humanized antibody that blocks the cleavage of complement factor 5, was approved for PNH treatment in 2007 and has improved patients' survival since then. However, several cases of invasive meningococcal disease (IMD) have been reported in eculizumab-treated patients, mostly caused by serogroup B infection which was not covered by the previously administered vaccine (MenACWY). We report a rare case of septic shock due to infection with Neisseria meningitis serogroup B despite prior vaccination with 4CMenB in a young PNH patient treated with eculizumab. There are increasing doubts over whether vaccination ensures sufficient immunoprotection against IMD in patients receiving eculizumab. Therefore, besides monitoring the immune response, lifelong chemoprophylaxis should be considered.",

keywords = "Journal Article",

author = "Dominik Reher and Valentin Fuhrmann and Stefan Kluge and Axel Nierhaus",

year = "2018",

month = may,

day = "3",

doi = "10.1016/j.vaccine.2018.03.087",

language = "English",

volume = "36",

pages = "2507--2509",

journal = "VACCINE",

issn = "0264-410X",

publisher = "Elsevier BV",

number = "19",

}

RIS

TY - JOUR

T1 - A rare case of septic shock due to Neisseria meningitidis serogroup B infection despite prior vaccination in a young adult with paroxysmal nocturnal haemoglobinuria receiving eculizumab

AU - Reher, Dominik

AU - Fuhrmann, Valentin

AU - Kluge, Stefan

AU - Nierhaus, Axel

PY - 2018/5/3

Y1 - 2018/5/3

N2 - Paroxysmal nocturnal haemoglobinuria (PNH) is a rare acquired haematopoietic stem cell disease which causes defects in complement inhibiting proteins. The disease presents classically with the triad of haemolytic anaemia, pancytopenia and thrombosis. Eculizumab, a humanized antibody that blocks the cleavage of complement factor 5, was approved for PNH treatment in 2007 and has improved patients' survival since then. However, several cases of invasive meningococcal disease (IMD) have been reported in eculizumab-treated patients, mostly caused by serogroup B infection which was not covered by the previously administered vaccine (MenACWY). We report a rare case of septic shock due to infection with Neisseria meningitis serogroup B despite prior vaccination with 4CMenB in a young PNH patient treated with eculizumab. There are increasing doubts over whether vaccination ensures sufficient immunoprotection against IMD in patients receiving eculizumab. Therefore, besides monitoring the immune response, lifelong chemoprophylaxis should be considered.

AB - Paroxysmal nocturnal haemoglobinuria (PNH) is a rare acquired haematopoietic stem cell disease which causes defects in complement inhibiting proteins. The disease presents classically with the triad of haemolytic anaemia, pancytopenia and thrombosis. Eculizumab, a humanized antibody that blocks the cleavage of complement factor 5, was approved for PNH treatment in 2007 and has improved patients' survival since then. However, several cases of invasive meningococcal disease (IMD) have been reported in eculizumab-treated patients, mostly caused by serogroup B infection which was not covered by the previously administered vaccine (MenACWY). We report a rare case of septic shock due to infection with Neisseria meningitis serogroup B despite prior vaccination with 4CMenB in a young PNH patient treated with eculizumab. There are increasing doubts over whether vaccination ensures sufficient immunoprotection against IMD in patients receiving eculizumab. Therefore, besides monitoring the immune response, lifelong chemoprophylaxis should be considered.

KW - Journal Article

U2 - 10.1016/j.vaccine.2018.03.087

DO - 10.1016/j.vaccine.2018.03.087

M3 - SCORING: Journal article

C2 - 29631884

VL - 36

SP - 2507

EP - 2509

JO - VACCINE

JF - VACCINE

SN - 0264-410X

IS - 19

ER -